Summary of Key Points Core Viewpoint - BGI Genomics (300676) has announced the approval of a foreign exchange hedging business for the year 2026 during its second extraordinary general meeting of shareholders held on November 12, 2025, indicating a strategic move to manage currency risk effectively [1]. Financial Performance - As of the market close on November 13, 2025, BGI Genomics' stock price was 49.18 yuan, reflecting a decrease of 0.65% from the previous trading day [1]. - The company's total market capitalization stood at 20.573 billion yuan, with a trading volume of 2.52 billion yuan and a turnover rate of 1.24% on the same day [1]. Shareholder Meeting Details - The extraordinary general meeting was conducted using a combination of in-person and online voting, with shareholder representatives holding 39.1127% of the total voting rights present [1]. - The legal opinion regarding the meeting was provided by Guohao Law Firm (Shenzhen), confirming the legality and validity of the meeting's convening, procedures, and voting results [1].

证券代码：300676 证券简称：华大基因 公告编号：2025-067 深圳华大基因股份有限公司 关于参加 2025 年度深圳辖区上市公司投资者 网上集体接待日活动的公告 为进一步加强与投资者的互动交流，深圳华大基因股份有限公司（以下简称 公司）将参加由深圳证监局和中证中小投资者服务中心指导、深圳上市公司协会 与深圳市全景网络有限公司联合举办的"2025 年度深圳辖区上市公司投资者网 上集体接待日活动"，现将相关事项公告如下： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2025 年 11 月 20 日（周四）14:30-17:00。届时公 司高管将在线就公司业绩、公司治理、发展战略、经营状况、融资计划、股权激 励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资 者踊跃参与！ 特此公告。 深圳华大基因股份有限公司董事会 2025年11月13日 ...

Group 1 - The ninth China (Shenzhen) Corporate Governance Summit was held with the theme "Governance Foundation, Market Value Renewal," focusing on strong regulation, risk prevention, and promoting high-quality development [1] - Xu Qian, Vice General Manager of BGI Genomics, emphasized the importance of corporate governance as a core element of modern enterprise systems, which serves as both a stabilizing force against risks and a source of innovation [1] - Companies are encouraged to understand the changing domestic and international landscape and adapt their strategies to seize opportunities in a rapidly evolving environment [1] Group 2 - The "2025 Greater Bay Area Listed Company Governance Evaluation Report" was released, indicating that the governance level of 803 listed companies in the Greater Bay Area is generally high, with an average governance index of 65.17, surpassing the national average of 64.94 [2] - The report highlights strong performance in shareholder governance, stakeholder governance, information disclosure, and board governance, while suggesting improvements in managerial and supervisory governance [2] - Recommendations include the establishment of governance guidelines for the Greater Bay Area and the development of a governance-oriented market value management system to enhance corporate governance quality [2] Group 3 - A specialized committee focusing on market value management was established to explore cutting-edge practices and compliance paths, aiming to create a positive cycle of value creation, capital recognition, and resource allocation in the Chinese capital market [3]

Core Insights - The Guangzhou government has introduced a policy to accelerate the development of future industries, designating the cell and gene industry as one of the six key sectors, which is seen as a significant boost for the industry [2][3] - The CEO of BGI Genomics, Zhao Lijian, emphasizes that this policy elevates the industry from enterprise-driven innovation to government-level design, providing essential support for innovation and development in the biological sector [2][4] - BGI Genomics is leveraging local policies and resources to expand its business, including a free genetic screening program for pregnant women in Guangzhou, supported by the local government [3][5] Industry Development - The new policy is expected to enhance the transformation of new technologies in the biological sector, with BGI Genomics planning to conduct clinical trials for new diagnostic technologies in Guangzhou [4] - Despite the widespread application of genetic testing, high costs remain a barrier to accessibility; however, BGI Genomics aims to reduce costs through self-sufficiency in technology and materials [4][6] - The integration of genetic testing into medical insurance is viewed as a long-term opportunity for the industry, despite potential short-term revenue pressures [6][7] Data Assetization - The value of genetic data is increasingly recognized, with a focus on ensuring data security and compliance during the assetization process [7] - BGI Genomics is collaborating with Shenzhen Data Exchange to ensure strict data asset certification, emphasizing the importance of privacy protection [7] - The company aims to utilize genetic data to support the development of innovative drugs for rare diseases, potentially reducing treatment costs and improving early diagnosis [7][8] Future Outlook - Zhao Lijian expresses confidence in the future of the gene industry, anticipating new opportunities driven by policy support, technological innovation, and the increasing value of data [8]

Core Viewpoint - BGI Genomics announced the resignation of its Vice President Li Ning due to work arrangements, while he will continue to serve as a board member and hold positions in the company's subsidiaries [1] Summary by Sections - **Company Announcement** - BGI Genomics (300676) released a notice on November 12 regarding the resignation of Li Ning from the position of Vice President [1] - Li Ning's original term was set from June 18, 2024, to June 17, 2027 [1]

Core Points - BGI Genomics announced the resignation of its Vice President Li Ning due to work arrangements, effective immediately upon receipt of the resignation report by the board [1] Group 1 - Li Ning will continue to serve as a director of the company after resigning from the Vice President position [1] - Li Ning will also maintain his role in the company's controlling subsidiary [1]

Company Overview - BGI Genomics (SZ 300676) announced on November 12 that Mr. Li Ning has resigned from his position as Vice General Manager due to work arrangements, but will continue to serve as a director of the company and hold positions in its controlling subsidiaries [1] Financial Performance - For the fiscal year 2024, BGI Genomics' revenue composition is projected to be 99.36% from the genomics application industry and 0.64% from other businesses [1] Market Position - As of the report date, BGI Genomics has a market capitalization of 20.7 billion yuan [1]

证券代码：300676 证券简称：华大基因 公告编号：2025-064 深圳华大基因股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要提示： 1、本次股东会召开期间不存在增加、否决或变更议案情形； 2、本次股东会未涉及变更前次股东会决议的情形。 一、会议召开情况 （1）现场会议召开时间：2025年11月12日（星期三）14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025年11月12日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网 投票系统投票的具体时间为2025年11月12日9:15至15:00的任意时间。 2、会议召开地点：广东省深圳市盐田区梅沙街道云华路9号华大时空中心 C 区国际会议中心417会议室 3、会议召开方式：本次股东会采取现场表决与网络投票相结合的方式 2025 年第二次临时股东会决议公告 1、会议召开的日期、时间： 4、会议召集人：公司董事会 5、会议主持人：公司董事长汪建先生因重要公务事项无法现场主持会议， 且公司未设置副董事长，由过半数的董事共 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 深圳华大基因股份有限公司（以下简称公司）董事会近日收到公司董事、副总经理 李宁先生的书面辞任报告。李宁先生因工作安排原因申请辞去公司副总经理职务，辞任 后继续担任公司董事，同时继续在公司的控股子公司担任职务。根据《深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》《公司章程》等相关规 定，李宁先生的辞任申请自公司董事会收到辞任报告之日起生效。 证券代码：300676 证券简称：华大基因 公告编号：2025-065 特此公告。 深圳华大基因股份有限公司 深圳华大基因股份有限公司董事会 关于高级管理人员辞任的公告 李宁先生作为公司高级管理人员原定任期为2024年6月18日至2027年6月17日。截至 本公告披露日，李宁先生直接持有公司股份122,600股，通过公司第二期员工持股计划持 有103.788万份持股计划份额；其关联人未持有公司股份。李宁先生在任职公司高管期间 不存在应当履行而未履行的承诺事项。李宁先生辞任公司副总经理职务后继续担任公司 董事，仍需遵守中国证监会、深圳证券交易所对于上市 ...

证券代码：300676 证券简称：华大基因 公告编号：2025-066 深圳华大基因股份有限公司 关于选举第四届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳华大基因股份有限公司（以下简称华大基因或公司）于2025年11月12 日召开2025年第二次临时股东会，审议通过了《关于变更注册资本并修订<公司 章程>的议案》，根据修订后的《深圳华大基因股份有限公司章程》相关规定，公 司在董事会中设职工代表董事1名，职工代表董事由公司职工通过职工代表大会、 职工大会或者其他形式民主选举产生，无需提交股东会审议。 为进一步完善公司治理结构，根据《中华人民共和国公司法》（以下简称《公 司法》）、《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范 运作》《上市公司章程指引》等相关法律法规、规范性文件及《公司章程》的规 定，公司于2025年11月12日在公司会议室召开职工代表大会，经与会职工代表表 决，选举张国成为公司第四届董事会职工代表董事（简历详见附件），任期自本 次职工代表大会选举通过之日起至第四届董事会任期届满之日止。 张国 ...